ThomasG.MartinMD

Hematology • San Francisco, CA

Professor, Medicine, UCSF School of Medicine

Join to view full profile

Dr. Martin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Martin's full profile

Already have an account?

Office
400 Parnassus Ave
San Francisco, CA 94143
Phone+1 415-353-2421

Fax+1 415-353-2467

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1993 - 1996
Los Angeles County-Harbor-UCLA Medical CenterResidency, Internal Medicine, 1989 - 1992
Uconn School Of MedicineClass of 1989

Certifications & Licensure

CA State Medical License 1991 - 2026
UT State Medical License 2013 - 2018
MO State Medical License 2012 - 2017
WA State Medical License 1996 - 2017
NE State Medical License 2015 - 2016
ME State Medical License 2014 - 2014
TX State Medical License 1999 - 2002
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer Start of enrollment: 1999 Jan 01
Completed
Not Applicable
Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Start of enrollment: 2002 Jan 01
Withdrawn
Phase 2
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer Start of enrollment: 2004 Sep 01
Completed
Phase 1
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer Start of enrollment: 2002 Oct 01
Completed
Phase 1
Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders Start of enrollment: 1999 Jan 01
Completed
Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors Start of enrollment: 2005 Aug 01
Completed
Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies Start of enrollment: 2004 Aug 01
Terminated
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies Start of enrollment: 2002 Oct 01
Terminated
Not Applicable
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT Start of enrollment: 2002 Nov 01
Completed
Phase 2
A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2004 Oct 01
Withdrawn
Phase 1, Phase 2
Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2004 Oct 28
Terminated
Phase 1, Phase 2
Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the Spine Start of enrollment: 2010 Feb 01
Completed
Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen Start of enrollment: 2009 Nov 01
Completed
Phase 1
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Join now to see all

Publications & Presentations

PubMed

2 citations
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, ...
Kwee Yong, Thomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Marcelo Capra
The Lancet. Haematology. 2024-10-01
4 citations
CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy.
Guy Ledergor, Zenghua Fan, Kai Wu, Elizabeth McCarthy, Axel Hyrenius-Wittsten
Blood Advances. 2024-07-09
7 citations
Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma.
Kevin R Reyes, Yen-Chun Liu, Chiung-Yu Huang, Rahul Banerjee, Thomas Martin
Blood Advances. 2024-05-14

Lectures

Approaches To Achieve the Best Possible Outcomes in Myeloma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Managing Multiple Myeloma: What's Next?
60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

FDA Approves New CAR T Cancer Therapy for Form of Multiple MyelomaFebruary 28th, 2022
New Data from CARTITUDE-1 Study Show Continued Deep and Durable Responses of Ciltacabtagene Autoleucel (Cilta-Cel) in Treatment of Heavily Pre-Treated Patients with Multiple MyelomaDecember 12th, 2021

ThomasG.MartinMD

Dr. Martin is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.